2023年9月27日 · VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today …

VBI-2901a is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes …

2023年12月26日 · They used this technology to design VBI-2901, a vaccine that expresses a modified prefusion form of spike proteins from SARS-CoV-2, SARS-CoV-1, and MERS-CoV. …

VBI’s enveloped virus-like particle (eVLP) coronavirus development programs (VBI-2900) are designed with the goal of providing broad protection, exceptional safety, and durability of …

2023年9月27日 · The VBI-2900 program consists of multiple undisclosed, multivalent vaccine constructs developed using VBI’s proprietary eVLP platform technology, in addition to the …

2020年5月18日 · During the first half of 2022, VBI expects to launch the first clinical study of VBI’s multivalent vaccine candidate (VBI-2901), designed to increase the breadth of protection …

2022年9月29日 · Initiation of first clinical study of multivalent VBI-2901, designed to increase breadth of protection against COVID-19 and related coronaviruses; Preclinical data support …

VBI-2901 is a multivalent pan-coronavirus vaccine candidate expressing a modified, optimized, pre-fusion form of the SARS-CoV-2 (COVID-19) spike antigen, as well as the SARS-CoV …

VBI-2901是由Vbi Vaccines Inc研发的一种预防性病毒性疫苗。 目前该药物最高研发阶段为临床一期，用于预防冠状病毒感染和新型冠状病毒感染。 VBI-2901-靶点_适应症: 冠状病毒感染-临 …

• Collaboration will combine VBI’s viral vaccine expertise, eVLP technology platform, and coronavirus antigens with the NRC’s uniquely-designed COVID- 19 antigens and assay …